Positives

• Roughly 400+ Long COVID patients have now received the same triple anticoagulation protocol, with most reporting symptom improvement within weeks of starting therapy Health Rising.
  
  

Negatives

• Long COVID patients prescribed apixaban after a COVID-19 hospital stay often report no meaningful improvement in their post-discharge symptoms or rehospitalization risk, and a small number have to discontinue because of major bleeding events University of Cambridge.
• A community feature on the microclot debate notes that out of 373 Long COVID patients treated with the Pretorius-style triple regimen, two had major bleeds (one requiring hospitalization) and bruising was common in the rest, echoing concerns from hematologists about the risk of paying out of pocket for an unproven approach Gavi.

Hurdles & Side Effects

• Patients on apixaban for the triple-anticoagulation protocol need close hematologist supervision because of the bleeding risk; those with a personal or family history of bleeding disorders are typically not offered the protocol at all MedHelp Clinics.
• Apixaban for Long COVID is off-label in the US and most insurance won’t cover it without a documented thrombosis indication, leaving patients to either pay $400-500/month out of pocket or pursue compassionate-use trials Pain Spa.